Hereditary susceptibility with MDM2 gene single nucleotide polymorphism for glioblastoma: Meta-analysis

doi:10.3877/cma.j.issn.2095-9141.2017.05.007

Abstract

Abstract:

Objective

To explore the association of MDM2 single nucleotide polymorphism with the risk of glioblastoma.

Methods

This study has searched a great number of papers using key terms based on PubMed, Google Scholar, CNKI, Baidu Scholar before screening samples. To investigate the interaction between MDM2 SNP309 and glioblastoma risk, was performed a Meta-analysis of the risk estimate on case-control studies from six qualified articles.

Results

The data we reviewed indicated that variant homozygote and heterozygote for MDM2 SNP309 were associated with an increased risk of glioblastoma by 1.23 on odds radio (OR) (95%CI: 1.05-1.44), P=0.288 by I² test; was performed variant heterozygote of SNP309 significantly increased the risk of cancer by 1.35 on OR (95%CI: 1.05-1.73). In a stratified analysis by ethnicity, this study certified that a significant increased risk in Caucasian by 1.30 on OR(95%CI: 1.08-1.57), P=0.410 by I² test.

Conclusion

The analysis indicate MDM2 SNP309 serves as a susceptibility marker on glioblastoma, which was clarified the different risks in ethnicity, especially in Caucasian with variant heterozygote.

Key words: MDM2 SNP309, Glioblastoma, Hereditary susceptibility, Meta-analysis

Jiajun Qin, Rongde Zhong, Xianzhen Chen. Hereditary susceptibility with MDM2 gene single nucleotide polymorphism for glioblastoma: Meta-analysis[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(05): 284-291.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2017.05.007

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2017/V03/I05/284

Figures/Tables 7

References 33

[1]	Momand J,Zambetti GP,Olson DC, et al. The oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation[J]. Cell, 1992, 69(7): 1237-1245.
[2]	Michael D,Oren M. The p53-Mdm2 module and the ubiquitin system[J]. Semin Cancer Biol, 2003, 13(1): 49-58.
[3]	Zhang Z,Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy[J]. Curr Cancer Drug Targets, 2005, 5(1): 9-20.
[4]	Bond GL,Hu W,Levine A, et al. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect[J]. Cancer Res, 2005, 65(13): 5481-5484.
[5]	Bond GL,Hu W,Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans[J]. Cell, 2004, 119(5): 591-602.
[6]	王倩,谭诗云,吴鹏波,等. MDM2-309 T/G基因多态性与食管癌易感性关系的Meta分析[J].疑难病杂志, 2017, 16(1): 75-79.
[7]	Marcel V,Palmero EI,Falagan-Lotsch P, et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis[J]. J Med Genet, 2009, 46(11): 766-772.
[8]	Grochola LF,Zeron-Medina J,Meriaux S, et al. Single-nucleotide polymorphisms in the p53 signaling pathway[J]. Cold Spring Harb Perspect Biol, 2010, 2(5): a001032.
[9]	Boersma BJ,Howe TM,Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309[J]. J Natl Cancer Inst, 2006, 98(13): 911-919.
[10]	Asomaning K,Reid AE,Zhou W, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis[J]. Clin Cancer Res, 2008, 14(12): 4010-4015.
[11]	Zhuo X,Ye H,Li Q, et al. Is MDM2 SNP309 variation a risk factor for head and neck carcinoma?: an updated meta-analysis based on 11,552 individuals[J]. Medicine(Baltimore), 2016, 95(9): e2948.
[12]	Yu H,Li H,Zhang J, et al. Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis[J]. Onco Targets Ther, 2016, 9: 6211-6224.
[13]	Yang XI,Zhu Y,Ye D, et al. Association of MDM2 promoter T309G polymorphism with oral cancer risk: a meta-analysis of 3,536 subjects[J]. Mol Clin Oncol, 2016, 5(1): 175.
[14]	Xue Z,Zhu X,Teng Y. Relationship between murine double minute 2 (MDM2) T309G polymorphism and endometrial cancer risk: a meta-analysis[J]. Med Sci Monit, 2016, 22: 3186-3190.
[15]	Xie L,Chen T,Hu H, et al. Association between MDM2 SNP309T>G polymorphism and the risk of bladder cancer: new data in Chinese population and an update meta-analysis[J]. Transl Androl Urol, 2016, 5(S1): AB265.
[16]	Wo X,Han D,Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis[J]. J Genet Genomics, 2011, 38(8): 341-350.
[17]	Wang LH,Wang X,Xu WT, et al. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis[J]. Tumour Biol, 2014, 35(4): 3167-3170.
[18]	Wan Y,Wu W,Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis[J]. BMC cancer, 2011, 11: 208.
[19]	Tian X,Wang B,Guo J, et al. The MDM2 T309G polymorphism and risk of lung cancer: an updated meta-analysis of 10,186 cases and 14,155 controls[J]. Panminerva Med, 2016, 58(4): 341-348.
[20]	Levav-Cohen Y,Goldberg Z,Tan KH, et al. The p53-Mdm2 loop: a critical juncture of stress response[J]. Subcell Biochem, 2014, 85:161-186.
[21]	He X,Chen P,Yang K, et al. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis[J]. Acta Haematol, 2015, 133(4): 365-371.
[22]	Gao J,Kang AJ,Lin S, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls[J]. Ther Clin Risk Manag, 2014, 10(1): 269-277.
[23]	Chen W,Wu Q,Ren H. Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk[J]. Biomed Rep, 2014, 2(1): 105-111.
[24]	Lei C,Zhang W,Fan J, et al. MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis[J]. Int J Clin Exp Med, 2015, 8(8): 13413-13416.
[25]	Bilbao-Aldaiturriaga N,Askaiturrieta Z,Granado-Tajada I, et al. A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility[J]. Pediatr Res, 2016, 80(4):472-479.
[26]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
[27]	杨军,刘运海. MDM2启动子309位点多态性与胶质母细胞瘤易感性的关系[J].山东医药, 2011, 51(29): 87-88.
[28]	Zawlik I,Kita D,Vaccarella S, et al. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas[J]. Brain Pathol, 2009, 19(2): 188-194.
[29]	Tsuiki H,Nishi T,Takeshima H, et al. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis[J]. Neurol Med Chir (Tokyo), 2007, 47(5): 203- 208.
[30]	Khatri RG,Navaratne K,Weil RJ. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme[J]. J Neurosurg, 2008, 109(5): 842-848.
[31]	El Hallani S,Marie Y,Idbaih A, et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis[J]. J Neurooncol, 2007, 85(3): 241-244.
[32]	Dimitriadi M,Poulogiannis G,Liu L, et al. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours[J]. Br J Cancer, 2008, 99(7): 1144-1152.
[33]	Hunziker A,Jensen MH,Krishna S. Stress-specific response of the p53-Mdm2 feedback loop[J]. BMC Syst Biol, 2010, 4: 94.

项目	条目	评判	得分
选择	研究病例是否恰当	是，独立确定	1
		是，自我报告	0
		非陈述	0
	病例的代表性	显著	1
	病例的代表性	有选择偏畸或未陈述	0
	选择对照	社区人群	1
		医院人群	0
		未陈述	0
	对照的特征	无相关疾病史	1
	对照的特征	未陈述	0
可比性	病例和对照可比性	控制了种族这一主要因素	1
可比性	病例和对照可比性	控制了年龄、基因型频率等因素	1
暴露	调查方法	可靠原始基因记录或盲法试验	1
		非盲法试验	0
		自我报告	0
		未陈述	0
	试验方法是否一致	是	1
		否	0
		2组相同	1
		陈述了无应答	0
		2组不同且缺乏标示	0

项目	条目	评判	得分
选择	研究病例是否恰当	是，独立确定	1
		是，自我报告	0
		非陈述	0
	病例的代表性	显著	1
	病例的代表性	有选择偏畸或未陈述	0
	选择对照	社区人群	1
		医院人群	0
		未陈述	0
	对照的特征	无相关疾病史	1
	对照的特征	未陈述	0
可比性	病例和对照可比性	控制了种族这一主要因素	1
可比性	病例和对照可比性	控制了年龄、基因型频率等因素	1
暴露	调查方法	可靠原始基因记录或盲法试验	1
		非盲法试验	0
		自我报告	0
		未陈述	0
	试验方法是否一致	是	1
		否	0
		2组相同	1
		陈述了无应答	0
		2组不同且缺乏标示	0

作者	年份	国家	人种	年龄组	病例组			对照组			HWE	检测方法	质量评价得分
作者	年份	国家	人种	年龄组	AA	GA	GG	AA	GA	GG	HWE	检测方法	选择	可比性	暴露
杨军等^[27]	2011	中国	亚洲	成人	28	42	25	29	52	14	是	PCR-RFLP	4	1	2
Khatri等^[30]	2008	美国	高加索	成人	5	79	14	23	74	5	否	PCR-sequencing	4	2	2
Zawlik等^[28]	2008	瑞士	高加索	成人	143	166	51	24	20	6	是	PCR-sequencing	4	2	3
El Hallani等^[31]	2007	法国	高加索	成人	98	114	42	109	96	33	是	PCR-sequencing	4	1	2
Dimitradi等^[32]	2008	英国	高加索	成人	34	27	9	24	20	6	是	PCR-sequencing	4	2	2
Tsuiki等^[29]	2007	日本	亚洲	成人	34	58	27	15	18	17	是	PCR-sequencing	4	1	2

作者	年份	国家	人种	年龄组	病例组			对照组			HWE	检测方法	质量评价得分
作者	年份	国家	人种	年龄组	AA	GA	GG	AA	GA	GG	HWE	检测方法	选择	可比性	暴露
杨军等^[27]	2011	中国	亚洲	成人	28	42	25	29	52	14	是	PCR-RFLP	4	1	2
Khatri等^[30]	2008	美国	高加索	成人	5	79	14	23	74	5	否	PCR-sequencing	4	2	2
Zawlik等^[28]	2008	瑞士	高加索	成人	143	166	51	24	20	6	是	PCR-sequencing	4	2	3
El Hallani等^[31]	2007	法国	高加索	成人	98	114	42	109	96	33	是	PCR-sequencing	4	1	2
Dimitradi等^[32]	2008	英国	高加索	成人	34	27	9	24	20	6	是	PCR-sequencing	4	2	2
Tsuiki等^[29]	2007	日本	亚洲	成人	34	58	27	15	18	17	是	PCR-sequencing	4	1	2

Please choose a citation manager

Content to export